1-4 of 4
Michaela L. Tsai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D. Soumerai, Catherine S. Diefenbach, Felipe Samaniego, Abhijeet Kumar, Michaela L. Tsai, Adam S. Asch, Deepa Jagadeesh, Vaishalee P. Kenkre, Izidore S. Lossos, Huda Salman, Farrukh T. Awan, Lu Miao, Richard G. Ghalie, Andrew D. Zelenetz
Journal: Blood
Blood (2022) 140 (Supplement 1): 189–191.
https://doi.org/10.1182/blood-2022-157563
Published: 2022
Journal Articles

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Tara L. Lin, MD, Pamela S. Becker, MD PhD, Prapti A. Patel, MD, Eunice S. Wang, MD, Alexander I. Spira, PhD MD FACP, Michaela L. Tsai, MD, Maya Ridinger, Peter J Croucher, PhD, Mark Erlander, PhD, Sandra L Silberman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 230.
https://doi.org/10.1182/blood-2019-126262
Published: 2019
Journal Articles

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

Jacob Laubach, MD, Andrew J Yee, MD, Jacalyn Rosenblatt, MD, Jeffrey V Matous, MD, Charles M. Farber, MDPhD, Thomas H. Openshaw, MD, Rodrigo O. Maegawa, MD, Michaela L. Tsai, MD, Irene M. Ghobrial, MD, Giada Bianchi, MD, Bhupendra Rawal, MS, Heidi Dipietro, RN, Kristen Cummings, RN, John Harran, RN, Peter O'Gorman, MD PhD FRCP, FRCPath, Kathleen Scott, PhD, Kathleen Fitzpatrick, Jennifer Abovich, Hannah Baker, Alexandra Savell, BS, Joshua Hansen, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 1981.
https://doi.org/10.1182/blood-2018-99-116280
Published: 2018
Journal Articles

Preliminary Safety, Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the Polo-like Kinase-1 (PLK1) Inhibitor PCM-075, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (D) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Alexander I Spira, MD, Prapti A. Patel, MD, Michaela L. Tsai, MD, Maya Ridinger, PhD, Sandra L Silberman, MD PhD, Mark Erlander, PhD, Jorge E. Cortes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4043.
https://doi.org/10.1182/blood-2018-99-112590
Published: 2018